PIK3CD and brain disorder: Several clinical trials have been initiated to test PI3K/mTOR antagonists for their efficacy to halt or reduce tumor growth [8], but more recently this pathway has also gained considerable attention for its dysregulation and potential applicability as a therapeutic target in other brain disorders, including epilepsy, schizophrenia, and autism spectrum disorders [9–13].